Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ENTX Stock Forecast 2025-2026
$1.99
Current Price
$95.00M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ENTX Price Targets
+402.5%
To High Target of $10.00
+402.5%
To Median Target of $10.00
+402.5%
To Low Target of $10.00
ENTX Price Momentum
-4.8%
1 Week Change
-2.9%
1 Month Change
-5.7%
1 Year Change
-6.1%
Year-to-Date Change
-28.7%
From 52W High of $2.79
+41.1%
From 52W Low of $1.41
📊 TOP ANALYST CALLS
Did ENTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Entera Bio is one of their latest high-conviction picks.
Latest ENTX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ENTX has a bullish consensus with a median price target of $10.00 (ranging from $10.00 to $10.00). Currently trading at $1.99, the median forecast implies a 402.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 402.5% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 402.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENTX Analyst Ratings
1
Buy
0
Hold
0
Sell
ENTX Price Target Range
Low
$10.00
Average
$10.00
High
$10.00
Current: $1.99
Latest ENTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 18, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Oct 7, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Sep 27, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Jun 5, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| May 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| May 13, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Apr 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $10.00 |
| Dec 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Sep 13, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Sep 11, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| May 8, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Apr 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Mar 28, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Sep 6, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $10.00 |
| Jul 19, 2022 | B. Riley Securities | Kalpit Patel | Buy | Maintains | $5.00 |
| Jun 16, 2021 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Mar 22, 2021 | Aegis Capital | Buy | Initiates | $0.00 | |
| Aug 3, 2018 | Maxim Group | Buy | Initiates | $0.00 |
Entera Bio Ltd. (ENTX) Competitors
The following stocks are similar to Entera Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Entera Bio Ltd. (ENTX) Financial Data
Entera Bio Ltd. has a market capitalization of $95.00M with a P/E ratio of -8.0x. The company generates $223,000 in trailing twelve-month revenue with a 5.0% profit margin.
Revenue growth is -48.8% quarter-over-quarter, while maintaining an operating margin of -6,102.4% and return on equity of -71.5%.
Valuation Metrics
Market Cap
$95.00M
Enterprise Value
$82.64M
P/E Ratio
-8.0x
PEG Ratio
-3.8x
Price/Sales
426.0x
Growth & Margins
Revenue Growth (YoY)
-48.8%
Gross Margin
N/A
Operating Margin
-6,102.4%
Net Margin
+5.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+13.9%
Current Ratio
13.1x
Debt/Equity
1.1x
ROE
-71.5%
ROA
-39.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Entera Bio Ltd. (ENTX) Business Model
About Entera Bio Ltd.
What They Do
Develops oral delivery solutions for large molecules.
Business Model
Entera Bio Ltd. operates as a clinical-stage biopharmaceutical company that focuses on creating orally administered therapeutics for large molecules that usually require injections. The company generates revenue through the development of innovative hormone therapeutics and biologics, leveraging proprietary technology to fill gaps in the market, particularly in treating conditions like osteoporosis and hypoparathyroidism.
Additional Information
As a pioneering player in the biotech industry, Entera Bio aims to improve patient adherence and treatment efficacy by transforming drug delivery systems. Their focus on addressing unmet medical needs positions them for potential significant impact in various therapeutic areas that rely on biological treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
18
CEO
Ms. Miranda J. Toledano M.B.A.
Country
Israel
IPO Year
2018
Website
www.enterabio.comEntera Bio Ltd. (ENTX) Latest News & Analysis
Latest News
Quick Summary
Entera Bio Ltd. (NASDAQ: ENTX) reported its financial results and key updates for Q1 2025 on May 9, focusing on oral peptide and protein replacement therapies.
Why It Matters
Entera Bio's financial results and business updates could impact its stock performance and investor sentiment, influencing market valuation and future investment opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Entera Bio Ltd. (NASDAQ: ENTX) announced its 2024 financial results and business achievements on March 28, 2025, focusing on oral peptide and protein replacement therapies.
Why It Matters
Entera Bio's financial results and business achievements signal its growth potential in the oral peptide market, impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
OPKO Health and Entera Bio have partnered to develop an oral dual agonist therapy for obesity and metabolic disorders. They plan to file an FDA Investigational New Drug application later this year.
Why It Matters
The collaboration between OPKO Health and Entera Bio could lead to a groundbreaking obesity treatment, potentially boosting both companies' stock values and attracting investor interest in innovative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Entera Bio to Participate in Upcoming Events
3 months ago
Quick Summary
Entera Bio Ltd. (NASDAQ: ENTX) will participate in upcoming conferences, focusing on its development of oral peptide and protein replacement therapies in tablet form.
Why It Matters
Entera Bio's participation in conferences signals potential investor interest and visibility, which may influence stock performance and market perception of its innovative therapy developments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
4 months ago
Quick Summary
Entera Bio Ltd. (NASDAQ: ENTX) will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025, available for investor meetings virtually.
Why It Matters
Entera Bio's participation in a major healthcare conference signals potential visibility and interest, which could influence stock performance and attract investor engagement.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Entera Bio Ltd. (NASDAQ: ENTX) reported its financial results and business updates for Q3 2024, emphasizing its focus on oral peptides and small therapeutic proteins.
Why It Matters
Entera Bio's financial results and updates may influence stock performance, indicating potential growth or risks in their oral peptide developments, impacting investor decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ENTX Stock
What is Entera Bio Ltd.'s (ENTX) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Entera Bio Ltd. (ENTX) has a median price target of $10.00. The highest price target is $10.00 and the lowest is $10.00.
Is ENTX stock a good investment in 2025?
According to current analyst ratings, ENTX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENTX stock?
Wall Street analysts predict ENTX stock could reach $10.00 in the next 12 months. This represents a 402.5% increase from the current price of $1.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Entera Bio Ltd.'s business model?
Entera Bio Ltd. operates as a clinical-stage biopharmaceutical company that focuses on creating orally administered therapeutics for large molecules that usually require injections. The company generates revenue through the development of innovative hormone therapeutics and biologics, leveraging proprietary technology to fill gaps in the market, particularly in treating conditions like osteoporosis and hypoparathyroidism.
What is the highest forecasted price for ENTX Entera Bio Ltd.?
The highest price target for ENTX is $10.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 402.5% increase from the current price of $1.99.
What is the lowest forecasted price for ENTX Entera Bio Ltd.?
The lowest price target for ENTX is $10.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 402.5% increase from the current price of $1.99.
What is the overall ENTX consensus from analysts for Entera Bio Ltd.?
The overall analyst consensus for ENTX is bullish. Out of 3 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are ENTX stock price projections?
Stock price projections, including those for Entera Bio Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 3:00 AM UTC